Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
第2相
実施中（募集終了）
NCT02893917
| 対象疾患 | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Carcinoma |
|---|
| 相 | 第2相 |
|---|
| スポンサー | National Cancer Institute (NCI) |
|---|
| ステータス | 実施中（募集終了） |
|---|
| 参加者数 | 90 名 |
|---|
| 介入（薬剤） | Cediranib, Olaparib |
|---|
| 開始日 | 2017年8月11日 |
|---|
| 完了日 | 2023年3月14日 |
|---|
| 結果公開日 | 2025年3月30日 |
|---|
概要
This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving olaparib and cediranib may help treat patients with castration-resistant prostate cancer.
Radiographic Progression Free Survival
Time interval from random assignment to the date when the first site of disease is found to progress, or death, whichever occurs first, assessed up to 5 years · months
| Arm A (Olaparib, Cediranib) | 8.5 months |
|---|
| Arm B (Olaparib) | 4.0 months |
|---|
| p-value | 0.0359 |
|---|
| Hazard Ratio (HR) | 0.617 (95% CI 0.392–0.969) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。